Literature DB >> 1700153

The Madigan prostatectomy.

A R Dixon1, P H Lord, M R Madigan.   

Abstract

A total of 59 patients with bladder outflow obstruction underwent the Madigan prostatectomy. The method, results and complications are described. For select patients with large benign adenomas without a median lobe or hematuria we believe the technique to be the operation of choice, particularly in younger patients. Advantages include absence of postoperative hematuria and clot retention, a decreased requirement for blood transfusions, a 16F postoperative catheter with early removal, avoidance of post-catheter stricture, a low rate of postoperative urinary infection, a short comfortable period of hospitalization and, in the long term (median followup 6 years), preservation of potency and antegrade ejaculation.

Entities:  

Mesh:

Year:  1990        PMID: 1700153     DOI: 10.1016/s0022-5347(17)39753-7

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  4 in total

1.  Modified madigan prostatectomy: a procedure preserved prostatic urethra intact.

Authors:  Jun Lu; Zhangqun Ye; Weilie Hu
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2005

2.  Extraperitoneal laparoscopic simple prostatectomy with urethra preservation using urethral initiation as the entry point: a practical approach for the treatment of benign prostatic obstruction.

Authors:  Shuhan Liu; Linyu Zhou; Jing Wang; Yiao Tan; Tao Huang; Jun Xiao
Journal:  World J Urol       Date:  2022-01-22       Impact factor: 4.226

3.  Laparoscopic simple prostatectomy with prostatic urethra preservation for benign prostatic hyperplasia.

Authors:  Nianzeng Xing; Yinglu Guo; Feiya Yang; Long Tian; Junhui Zhang; Yong Yan; Ning Kang; Zhongcheng Xin; Yinong Niu
Journal:  Transl Androl Urol       Date:  2012-03

Review 4.  Ejaculations and Benign Prostatic Hyperplasia: An Impossible Compromise? A Comprehensive Review.

Authors:  Nicolas Couteau; Igor Duquesne; Panthier Frédéric; Nicolas Thiounn; Marc-Olivier Timsit; Arnaud Mejean; Ugo Pinar; François Audenet
Journal:  J Clin Med       Date:  2021-12-10       Impact factor: 4.241

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.